Test your knowledge on managing steroid-dependent skin GvHD

What determines whether GvHD is “steroid dependent?”
Partial response by day 56 of initial therapy
Steroid sensitivity but still receiving >10 mg/m2 per day of prednisone by day 56
A flare requiring a ≥25% increase in steroid dose without other therapies
Steroid sensitivity but still receiving steroids beyond day 80 of acute GvHD treatment
Any of the above
What determines whether GvHD is considered acute or chronic?
Clinical characteristics
Occurrence <100 days or ≥100 days
Mild skin rash
None of the above
Current FDA-approved therapies for chronic GvHD include:
Bleomycin, ruxolitinib, and obinutuzumab
Ruxolitinib, obinutuzumab, and ibrutinib
Belumosudil, ruxolitinib, and ibrutinib
Obinutuzumab, ibrutinib, belumosudil
{"name":"Test your knowledge on managing steroid-dependent skin GvHD", "url":"https://www.poll-maker.com/Q4IH2NK4M","txt":"What determines whether GvHD is “steroid dependent?”, What determines whether GvHD is considered acute or chronic?, Current FDA-approved therapies for chronic GvHD include:","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys